ATE283285T1 - Globularer aufbau vom amyloid-beta- protein und deren verwendungen - Google Patents

Globularer aufbau vom amyloid-beta- protein und deren verwendungen

Info

Publication number
ATE283285T1
ATE283285T1 AT00952571T AT00952571T ATE283285T1 AT E283285 T1 ATE283285 T1 AT E283285T1 AT 00952571 T AT00952571 T AT 00952571T AT 00952571 T AT00952571 T AT 00952571T AT E283285 T1 ATE283285 T1 AT E283285T1
Authority
AT
Austria
Prior art keywords
addls
activity
formation
amyloid beta
compounds
Prior art date
Application number
AT00952571T
Other languages
English (en)
Inventor
Grant A Krafft
William L Klein
Brett A Chromy
Mary P Lambert
Caleb E Finch
Todd Morgan
Pat Wals
Irina Rozovsky
Ann Barlow
Original Assignee
Univ Southern California
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23454671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE283285(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Southern California, Univ Northwestern filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE283285T1 publication Critical patent/ATE283285T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT00952571T 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen ATE283285T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36923699A 1999-08-04 1999-08-04
PCT/US2000/021458 WO2001010900A2 (en) 1999-08-04 2000-08-04 Globular assembly of amyloid beta protein and uses thereof

Publications (1)

Publication Number Publication Date
ATE283285T1 true ATE283285T1 (de) 2004-12-15

Family

ID=23454671

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00952571T ATE283285T1 (de) 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen
AT04027742T ATE445639T1 (de) 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04027742T ATE445639T1 (de) 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen

Country Status (9)

Country Link
EP (2) EP1571158B1 (de)
JP (1) JP4796725B2 (de)
AT (2) ATE283285T1 (de)
AU (1) AU6524500A (de)
CA (1) CA2381323C (de)
DE (2) DE60043165D1 (de)
ES (1) ES2235926T3 (de)
HK (1) HK1047944A1 (de)
WO (1) WO2001010900A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
EP1309341A2 (de) 2000-07-07 2003-05-14 Lars Lannfelt Prävention und behandlung der alzheimer krankheit
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
PT1944040E (pt) 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
EP1288226A1 (de) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modifizierung der Geneexpression der Mitglieder von "Toll"-ähnlicher Rezeptorfamilie zur Beeinflussung der Neurodegeneration und der Neuroprotektion im menschlichen Zentralnervensystem
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003262553A1 (en) * 2002-07-31 2004-02-23 Solvias Ag Device and method for measurement
WO2004031400A2 (en) * 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US8250823B2 (en) 2003-08-26 2012-08-28 Ejot Gmbh & Co. Kg Dowels and methods for the assembly of insulating panels
AU2005244013A1 (en) * 2004-05-14 2005-11-24 Acumen Pharmaceuticals, Inc. Compositions comprising ADDL receptor syngap
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2006094724A2 (en) 2005-03-05 2006-09-14 Abbott Gmbh & Co. Kg Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
DE102005014936A1 (de) 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
TW200726774A (en) * 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) * 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
US8263558B2 (en) 2005-11-30 2012-09-11 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2121754E (pt) 2007-01-18 2015-05-11 Lilly Co Eli Fab de beta-amilóide peguilado
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009079566A2 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
PT2448968T (pt) * 2009-06-29 2021-04-30 Bioarctic Ab ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL
EP2368558A1 (de) 2010-03-23 2011-09-28 Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch Azoverbindungen zur Reduzierung der Bildung und der Toxizität von Amyloid-Beta-Aggregationszwischenprodukten
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
AU2012282825B2 (en) 2011-07-13 2016-05-26 Merck Sharp & Dohme Corp. Method for detection of amyloid beta oligomers in a fluid sample and uses thereof
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
EP3166970B1 (de) 2014-07-10 2021-03-10 BioArctic AB Verbesserte ass-protofibrilenbindende antikörper
WO2019018445A1 (en) * 2017-07-17 2019-01-24 Maxwell Biosciences, Inc. POLYTHERAPY MODULATING THE MODULATION OF CATHELICIDINE GENE EXPRESSION FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISEASES
WO2023107830A1 (en) * 2021-12-06 2023-06-15 The Board Of Trustees Of The Leland Stanford Junior University Amyloid oligomer compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
EP1007048A4 (de) * 1997-03-11 2004-09-22 Gen Hospital Corp Identifizierung von mitteln zur behandlung der alzheimerischen krankheit

Also Published As

Publication number Publication date
EP1571158A3 (de) 2007-03-14
EP1571158B1 (de) 2009-10-14
EP1200470A2 (de) 2002-05-02
CA2381323C (en) 2009-10-06
ATE445639T1 (de) 2009-10-15
DE60016227D1 (de) 2004-12-30
DE60043165D1 (de) 2009-11-26
JP4796725B2 (ja) 2011-10-19
WO2001010900A3 (en) 2001-08-30
AU6524500A (en) 2001-03-05
EP1571158A2 (de) 2005-09-07
JP2003510023A (ja) 2003-03-18
WO2001010900A2 (en) 2001-02-15
HK1047944A1 (zh) 2003-03-14
EP1200470B1 (de) 2004-11-24
ES2235926T3 (es) 2005-07-16
DE60016227T2 (de) 2005-12-15
CA2381323A1 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
ATE283285T1 (de) Globularer aufbau vom amyloid-beta- protein und deren verwendungen
ATE349467T1 (de) Amyloid beta protein (globularer aufbau und seine verwendung)
WO2004031400A3 (en) Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
ATE485303T1 (de) Isoformen von gehirn-natriuretischem peptid
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
WO2003104437A3 (en) Anti-addl antibodies and uses thereof
DE60034957D1 (de) Zusammensetungen und verfahren zur modulation von apoptose in cellen, die proteine der bc1-2-familie exprimieren
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
KR890700666A (ko) 혈관 항응고 단백질, 이를 암호화하는 dna, 이의 제조방법 및 용도
ATE537186T1 (de) P53-bindendes polypeptid
WO2000013015A8 (en) Modulating multiple lineage kinase proteins
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
WO2000052151A3 (en) Human secretory proteins
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
BR9811907A (pt) Proteìna de ligação de lactoferrina de neisseria
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
WO2002014536A3 (en) Odulating multiple lineage kinase proteins
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
WO2004013629A3 (en) Screening for agents suitable for treatment of leukocyte associated inflammatory diseases
NO920524L (no) Kynurensyrederivater, deres fremstilling og farmasoeytiskeblandinger inneholdende disse
WO2000078952A3 (en) Human rna metabolism proteins (rmep)
ATE338714T1 (de) Überladebrücke
WO2000049043A3 (en) Human lipid-associated proteins
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin
WO2004019880A3 (en) Aw755252-interacting proteins and use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties